French Hypertrophic Cardiomyopathy Observatory
ConditionHypertrophic Cardiomyopathy
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age15+
SponsorFrench Cardiology Society
About this trial
Hypertrophic cardiomyopathy (Hypertrophic CardioMyopathy=HCM) remains a poorly understood disease with an assumption insufficiently codified. There is no data available in France on the profile of patients, diagnostic methods and assessment and therapeutic use.
The purpose of this study is to establish a monitoring of patients with HCM (sarcomere of origin or not) in France (diagnosis, treatment)
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Age ≥ 15 years old
Patient with HCM defined by an ultrasound thickness of the left ventricle ≥ 13 mm if familial or ≥ 15 mm if sporadic
Disqualifiers
Expressed refusal to participate in the study
Significant aortic stenosis (<1 cm ²)
Trial population
Patients ≥ 15 years old with HCM (sarcomere of origin or not) defined by an ultrasound thickness of the left ventricle ≥ 13 mm if familial or ≥ 15 mm if sporadic
Trial design
Design model
Cohort
Time perspective
Other
Treatments tested in this trial
Not listed
Trial groups
600 Participants
are grouped into 1 trial groupGroup A: Patients with HCM
Trial outcomes
Primary outcomes
1
Event-free survival
Time frame
3 yearsSecondary outcomes
1
Diagnostic methods
Define the profile of patients with HCM in France, diagnostic methods, evaluation (diagnostic investigation and family) and therapeutic. Who are the patients CMH France? (rules discovery, clinical presentation) and how are assumed the HCM in France? (examinations, hospitalizations, treatments, procedures for the family survey).
Time frame
0 daySponsors and contacts
Click on the lead sponsor to view all of their trials.
Source ClinicalTrials.gov